Fragment 176-191

HGH Fragment 176-191 (commonly referred to as Fragment 176-191 or AOD-9604 derivative) is a modified synthetic peptide representing the C-terminal region (amino acids 176 through 191) of human growth hormone (hGH).

This specific domain is responsible for the lipolytic (fat-burning) properties of full-length growth hormone. By isolating only the lipolytic domain, Fragment 176-191 triggers fat oxidation and inhibits lipogenesis without impacting insulin sensitivity, blood glucose levels, or cell proliferation, avoiding the diabetogenic side effects associated with full recombinant hGH.

Key Benefits & Applications

• Targeted Fat Loss (Lipolysis): Stimulates lipolysis (breakdown of triglycerides into free fatty acids) specifically in stubborn visceral and subcutaneous adipose tissues.

• Inhibition of Lipogenesis: Prevents the conversion and accumulation of new dietary fats into adipose stores.

• Preservation of Glycemic Control: Does not induce insulin resistance, hyperglycemia, or blood sugar spikes, making it safer for metabolism than full-length hGH.

• Lean Tissue Preservation: Promotes fat oxidation for energy utilization without catabolizing existing muscle tissue.

• No Impact on IGF-1 Levels: Does not elevate circulating IGF-1, eliminating risks associated with organ growth or systemic cell proliferation.